Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

v3.19.1
CONCENTRATIONS
3 Months Ended
Mar. 31, 2019
Notes to Financial Statements  
Note 14 - CONCENTRATIONS

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

 

The Company’s revenues earned from sale of products and services for the three months ended March 31, 2019 included 13%, 32%, 30% and 14% (aggregate of 89%) from four customers of the Company’s total revenues.

 

The Company’s revenues earned from sale of products and services for the three months ended March 31, 2018 included 14%, 23% and 13% (aggregate of 50%) from three customers of the Company’s total revenues.

 

Four customers accounted for 20%, 15%, 16% and 35% (aggregate of 86%) of the Company’s total accounts receivable at March 31, 2019 and three customers accounted for 44%, 17% and 32% (aggregate of 93%) of the Company’s total accounts receivable at December 31, 2018.

 

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.